Alps Advisors Inc. decreased its stake in shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 17.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 103,816 shares of the biotechnology company’s stock after selling 21,839 shares during the quarter. Alps Advisors Inc.’s holdings in Adaptimmune Therapeutics were worth $693,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Adaptimmune Therapeutics by 2.5% during the 1st quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock worth $9,062,000 after purchasing an additional 19,765 shares during the period. Dorsey Wright & Associates bought a new position in shares of Adaptimmune Therapeutics during the 2nd quarter worth about $6,981,000. Baillie Gifford & Co. increased its holdings in shares of Adaptimmune Therapeutics by 18.2% during the 2nd quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock worth $36,005,000 after purchasing an additional 467,852 shares during the period. NEA Management Company LLC increased its holdings in shares of Adaptimmune Therapeutics by 10.9% during the 1st quarter. NEA Management Company LLC now owns 13,332,611 shares of the biotechnology company’s stock worth $149,725,000 after purchasing an additional 1,306,612 shares during the period. Finally, Fred Alger Management Inc. bought a new position in shares of Adaptimmune Therapeutics during the 2nd quarter worth about $297,000. Institutional investors own 59.32% of the company’s stock.
A number of analysts recently weighed in on the stock. Raymond James set a $20.00 target price on shares of Adaptimmune Therapeutics and gave the company a “buy” rating in a research note on Wednesday, May 9th. SunTrust Banks upped their target price on shares of Adaptimmune Therapeutics to $18.00 and gave the company a “buy” rating in a research note on Thursday, May 10th. Cowen reissued a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Wednesday, May 9th. ValuEngine raised shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Finally, Leerink Swann upped their target price on shares of Adaptimmune Therapeutics to $20.00 and gave the company an “outperform” rating in a research note on Monday, June 4th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $16.94.
In related news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the company’s stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total value of $256,250.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 26.47% of the company’s stock.
NASDAQ ADAP opened at $10.86 on Thursday. The stock has a market capitalization of $1.09 billion, a P/E ratio of -13.74 and a beta of 1.09. Adaptimmune Therapeutics PLC – has a twelve month low of $6.60 and a twelve month high of $14.63.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.20). The business had revenue of $9.04 million during the quarter, compared to the consensus estimate of $7.76 million. Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%. equities analysts expect that Adaptimmune Therapeutics PLC – will post -1.02 EPS for the current year.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
See Also: Marijuana Stocks Future Looks Bright
Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics PLC – (NASDAQ:ADAP).
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.